BeiGene, Ltd. (ONC)vsTscan Therapeutics Inc (TCRX)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
TCRX
Tscan Therapeutics Inc
$1.03
-0.96%
HEALTHCARE · Cap: $58.61M
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 51649% more annual revenue ($5.34B vs $10.32M). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
TCRX
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for TCRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
2.9% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : TCRX
The strongest argument for TCRX centers on Price/Book.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : TCRX
The primary concerns for TCRX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while TCRX is a value play — different risk/reward profiles.
TCRX carries more volatility with a beta of 1.03 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 40/100) and 32.8% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Tscan Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tscan Therapeutics Inc (TCRX) is a clinical-stage biotechnology firm that specializes in advancing immunotherapy through its proprietary T cell receptor (TCR) discovery platform, targeting specific cancer antigens to offer precision medicine solutions in oncology. The company is focused on developing innovative TCR-based therapeutics aimed at translating scientific advancements into effective treatment options for various cancers and diseases, ultimately improving patient outcomes. With a strong therapeutic pipeline and a comprehensive intellectual property portfolio, Tscan Therapeutics is well-positioned to become a leader in the rapidly evolving landscape of T cell-based therapies.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?